M&A / Deals Vertex buys Crinetics for $10bn in endocrinology drive PharmaphorumVertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly.Rare DiseaseRead full story pharminent July 7, 2026 (Last updated: July 8, 2026) Pharmaphorum Vertex has made the largest acquisition in its history, agreeing to buy Crinetics in a $10bn deal that adds an approved therapy for acromegaly. Rare Disease Read full story Post navigation Previous: EC approves AbbVie’s Tepkinly combination for follicular lymphomaNext: Vera’s TRUTAKNA Wins FDA Accelerated Approval for IgA Nephropathy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
